The chronic obstructive pulmonary disease market is becoming increasingly crowded, and market access in the EU5 is a growing concern as manufacturers attempt to achieve favorable reimbursement status. In 2015, several new combination therapies have been approved for the treatment of COPD, payers are becoming stricter on HTA evaluations, requiring active comparators in clinical trials. Additionally, cost-conscious EU payers anticipate the launch of generic version of market leaders Spiriva and Seretide, which may displace or force these therapies to accept a lower price. Emerging FDCs will also compete against open combinations of older therapies, making favorable reimbursement a requirement to achieve market uptake.
- Chronic Obstructive Pulmonary Disease - Access & Reimbursement - Detailed, Expanded Analysis (EU)
Author(s): Kristine Mackin, PhD
Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.
She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.